- Home
- ETON vs ALDX Comparison
ETON vs ALDX Comparison
Compare ETON & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ALDX
- Stock Information
- Founded
- ETON 2017
- ALDX 2004
- Country
- ETON United States
- ALDX United States
- Employees
- ETON N/A
- ALDX N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- ALDX Health Care
- Exchange
- ETON Nasdaq
- ALDX Nasdaq
- Market Cap
- ETON 329.8M
- ALDX 304.9M
- IPO Year
- ETON 2018
- ALDX 2014
- Fundamental
- Price
- ETON $15.29
- ALDX $6.31
- Analyst Decision
- ETON Strong Buy
- ALDX Strong Buy
- Analyst Count
- ETON 3
- ALDX 2
- Target Price
- ETON $24.00
- ALDX $10.00
- AVG Volume (30 Days)
- ETON 245.8K
- ALDX 640.9K
- Earning Date
- ETON 05-08-2025
- ALDX 05-01-2025
- Dividend Yield
- ETON N/A
- ALDX N/A
- EPS Growth
- ETON N/A
- ALDX N/A
- EPS
- ETON N/A
- ALDX N/A
- Revenue
- ETON $34,677,000.00
- ALDX N/A
- Revenue This Year
- ETON $22.19
- ALDX N/A
- Revenue Next Year
- ETON $109.55
- ALDX N/A
- P/E Ratio
- ETON N/A
- ALDX N/A
- Revenue Growth
- ETON 5.64
- ALDX N/A
- 52 Week Low
- ETON $3.03
- ALDX $2.75
- 52 Week High
- ETON $18.41
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ETON 51.28
- ALDX 50.42
- Support Level
- ETON $14.28
- ALDX $6.79
- Resistance Level
- ETON $15.02
- ALDX $7.20
- Average True Range (ATR)
- ETON 0.90
- ALDX 0.60
- MACD
- ETON 0.04
- ALDX -0.01
- Stochastic Oscillator
- ETON 70.78
- ALDX 63.22
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.